How cachexia affects lung cancer treatment with immune therapy
Cachexia-mediated FcRn Modulation and Its Impact on Anti-PD1 Therapy in Lung Cancer
This study is looking at how severe weight loss and muscle loss, known as cachexia, affects the success of a lung cancer treatment called anti-PD1 therapy, to help find ways to make this treatment work better for patients dealing with both lung cancer and cachexia.
Quick facts
| Grant type | R01 grant |
|---|---|
| Study type | NIH-funded research |
| Funding institution | Ohio State University NIH-funded |
| Lab location | 1 site (Columbus, UNITED STATES) |
| Project ID | NIH-10906306 on NIH RePORTER |
What this research studies
This research investigates the impact of cachexia, a condition characterized by severe weight loss and muscle wasting, on the effectiveness of anti-PD1 therapy in lung cancer patients. The study aims to understand how cachexia alters immune responses and the clearance of therapeutic antibodies in the body. By examining both human patients and animal models, the researchers will explore the role of the neonatal Fc receptor (FcRn) in modulating immune responses and its potential influence on treatment outcomes. The goal is to identify mechanisms that could improve the effectiveness of immune therapies for patients suffering from lung cancer and cachexia.
Who could benefit from this research
Good fit: Ideal candidates for this research are lung cancer patients who are experiencing cachexia.
Not a fit: Patients without lung cancer or those who do not have cachexia may not benefit from this research.
Why it matters
Potential benefit: If successful, this research could lead to improved treatment strategies for lung cancer patients with cachexia, enhancing their response to immune therapies.
How similar studies have performed: Previous research has indicated that understanding the relationship between cachexia and immune response can lead to better treatment outcomes, suggesting potential success for this approach.
Where this research is happening
Columbus, UNITED STATES
- Ohio State University — Columbus, United States (Active)
Researchers
- Principal investigator: Phelps, Mitch a — Ohio State University
- Study coordinator: Phelps, Mitch a
About this research
- This is an active NIH-funded research project — typically early-stage science, not a clinical trial accepting patient enrollment.
- Some NIH-funded labs run parallel clinical studies or seek volunteers for related work. To check, contact the principal investigator or institution listed above.
- For full project details, budget, and progress reports, visit the official NIH RePORTER page below.